Repatha evolocumab

The single biggest commercial risk is not side effects but the insurance-access-to-abandonment pipeline: patients who fight through prior auth, pay high copays, then quit at dose 2 over pain that resolves in months if they persist.

• Repatha delivers dramatic LDL reductions (often 60-90 points) that statin-intolerant FH and CVD patients call life-changing, but a near-equal share report debilitating musculoskeletal pain that their physicians frequently dismiss as unrelated.
• Insurance prior authorization friction and Medicare cost spikes are the most-cited structural barriers to initiation and persistence, sometimes forcing mid-therapy switches to Praluent that patients did not choose and did not want.
• The long half-life (11-17 days) turns every side-effect decision into a 2-3 month commitment, amplifying anxiety at dose 2 when most musculoskeletal and GI events first appear, making early peer reassurance critical.
• A vocal minority of long-term users (2-plus years) report delayed-onset leg weakness, GI cycling, and blurry vision that are not prominently labeled, fueling physician-distrust narratives and early-stage litigation discussion online.